Trial Profile
A Phase-IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects Treated With Lanthanum Carbonate (Fosrenol)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Mar 2021
Price :
$35
*
At a glance
- Drugs Lanthanum carbonate (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions
- Sponsors Shire
- 15 Jun 2016 Status changed from active, no longer recruiting to completed.
- 15 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016.
- 15 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016.